Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis Clinical Trial

Official title:

A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02228213
• Other study ID #: MIS416-202
• Secondary ID: U1111-1166-0910
• Status: Completed
• Phase: Phase 2
• First received: August 21, 2014
• Last updated: July 12, 2017
• Start date: October 2014
• Est. completion date: June 2017

Study information

• Verified date: July 2017
• Source: Innate Immunotherapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether MIS416 administered once weekly over 12 months is safe, tolerable, and improves a range of signs and symptoms associated with secondary progressive multiple sclerosis.

Description:

The primary objectives of the study are to:

1. Determine the efficacy of MIS416, relative to placebo, when administered repeatedly via weekly intravenous (IV) administration to subjects with Secondary Progressive Multiple Sclerosis, as assessed by its effect on measures of neuromuscular function.

2. Determine the safety and tolerability of a weekly regimen of MIS416.

The secondary objectives of the study are to:

1. Determine the effect of MIS416 on disease activity and neurodegeneration by assessing changes in Magnetic Resonance Imaging (MRI) markers including lesions, whole brain atrophy (WBA) and Magnetization Transfer Ratio (MTR).

2. Determine the effect of MIS416 on Patient Reported Outcomes (PRO) related to disability and health status.

3. Assess, in a subset of subjects, the pharmacodynamic (PD) effects of MIS416, including effects on serum, Peripheral Blood Mononuclear Cell (PBMC), and Cerebral Spinal Fluid (CSF) cytokine/chemokine levels and expression patterns.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: June 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. A historical or current cranial MRI scan demonstrating T2-hyperintense lesions consistent with MS.

2. Has SPMS as determined by the 2010 Update to the McDonald Criteria

3. An Expanded Disability Status Scale (EDSS) of 3.0 to 6.5 at Screening.

4. Has SPMS which, in the judgment of the investigator, has been clinically active and functionally progressive within the 2 years prior to Screening

5. The absence of MS relapse for at least two years prior to Baseline.

6. Neurologically stable for at least four weeks prior to Screening.

7. Has the following laboratory values within three days prior to initiation of Investigational Product:

• Absolute neutrophil count (ANC) >= 1 x 109/L;

• Platelet count >= 100 x 109/L;

• Serum creatinine =< 1.5 mg/dL;

• Aspartate aminotransferase (AST) =<2 × upper limit of normal;

• Alanine aminotransferase (ALT) =< 2 × upper limit of normal.

8. Provided written informed consent to participate.

Exclusion Criteria:

1. Has primary Progressive MS (PPMS), Relapsing Remitting (RRMS), or progressive relapsing MS as determined by the 2010 update to the McDonald Criteria.

2. Has not completed the discontinuation period for approved and/or investigational multiple sclerosis disease modifying therapies prior to screening.

3. Has had any other immunomodulatory drug therapy or immunosuppressive therapy within four weeks prior to Screening, or systemic corticosteroids within the eight weeks prior to Screening.

4. Any previous exposure to investigational MS therapeutic vaccines.

5. Any use of cell-depleting monoclonal antibodies including, but not limited to, Rituximab, or Ocrelizumab.

6. A diagnosis or history of collagen vascular disease (including Sjögren's syndrome and systemic lupus erythematosus), anticardiolipin antibody syndrome, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, sarcoidosis, vasculitis, Behcet's syndrome and/or Lyme disease.

7. Contraindication to MRI (e.g., pacemaker or other contraindicated implanted metal device, allergy to gadolinium, or unmanageable claustrophobia).

8. A history of alcohol or drug abuse (including cannabinoid use) within two years prior to Screening.

9. Has had major surgery or radiation therapy within four weeks prior to Screening.

10. Has an active infection requiring antibiotics within two weeks prior to Screening.

11. Has had active malignancy within two years of Screening, with the exception of basal cell carcinoma and squamous cell carcinoma of the skin.

12. Uncontrolled congestive heart failure, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or transient ischemic attack within twelve weeks prior to Screening.

13. Has angina, other symptomatic coronary artery disease, or known cardiomyopathy.

14. Has symptomatic cardiac dysrhythmias requiring treatment, or persistent prolongation of the QTcF (Fredericia) interval to > 450 msec for males or > 470 msec for females.

Related Conditions & MeSH terms

• Multiple Sclerosis
• Multiple Sclerosis, Chronic Progressive
• Neoplasm Metastasis
• Sclerosis
• Secondary Progressive Multiple Sclerosis

Intervention

Biological:
• MIS416
Intravenous administration weekly for 52 weeks

Drug:
• Saline
Intravenous administration weekly for 52 weeks

Locations

Country	Name	City	State
Australia	PARC Clinical Research	Adelaide	South Australia
Australia	The Wesley-St. Andrew's Research Institute	Brisbane	Queensland
Australia	Nucleus Network - Centre for Clinical Studies	Melbourne	Victoria
Australia	Western Australian Neuroscience Research Institute	Perth	Western Australia
Australia	Neurodegenerative Disorders Research	West Perth	Western Australia
New Zealand	Optimal Clinical Trials	Auckland
New Zealand	P3 Research	Wellington

Sponsors (2)

Lead Sponsor	Collaborator
Innate Immunotherapeutics	INC Research

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline of neuromuscular function at 12 months	Neuromuscular function will be assessed using the following test: MS Function Composite (MSFC), comprising the; timed 25 Foot Walk, 9 Hole Peg Test (9HPT), and Paced Auditory Serial Addition Test (PASAT); Jebsen Hand Function Test (JHFT); Grip, tip and key pinch strength; Symbol digit modalities test (SDMT); Sloan low-contrast letter visual acuity (SLCVA); 6-minute walk test (6MWT);	Baseline, 3, 6, 9 and 12 months
Primary	Proportion of Participants with Serious and Non-Serious Adverse Events	Safety assessments will be conducted at each study visit and include; characterization of the type, incidence, severity, timing, seriousness, and relationship to treatment of adverse events (AEs); effects on vital signs and clinical laboratory parameters; changes on electrocardiograms (ECGs); and at 3 months and 12 months - the number of gadolinium-enhancing lesions on cranial MRI assessments.	Up to 12 months
Secondary	Change from baseline of disability and health status at 12 months	Disability and health status will be assessed using the following assessments and patient reported outcomes: Expanded Disability Status Scale (EDSS); Patient Reported Outcomes (PROs) including; SF-36 and its components; MS Impact Scale (MSIS-29); Neurological Fatigue Index for MS (NFI-MS); Brief Pain Inventory (BPI).	Baseline, 3, 6, 9, and 12 months
Secondary	Change from baseline of neurodegeneration by assessing changes in Magnetic Resonance Imaging (MRI) markers at 12 months	Disease activity and neurodegeneration will be assessing using Magnetic Resonance Imaging (MRI) markers including lesions, whole brain atrophy (WBA) and Magnetization Transfer Ratio (MTR).	Baseline, 3, and 12 months
Secondary	Change from baseline of activity of immune biomarkers in serum	The effect on immune biomarkers will include the analysis of serum for some or all of the following markers: IP-10 (CXCL10), MCP-1 (CCL2), MIG (CXCL9), IL-8 (CXCL8), IFN?, Neopterin, IL-1RA, sTNF-R, IL-12/23, p40, CD62E (E-selectin), CD54 (ICAM-1), and CD106 (VCAM-1).	Up to 1 year
Secondary	Change from baseline of activity of immune biomarkers in cerebrospinal fluid (CSF)	The effect on immune biomarkers will include the analysis of CSF for some or all of the following markers: IP-10 (CXCL10), MCP-1 (CCL2), MIG (CXCL9), IL-8 (CXCL8), IFN?, Neopterin, IL-1RA, sTNF-R, IL-12/23, p40, CD62E (E-selectin), CD54 (ICAM-1), and CD106 (VCAM-1).	Up to 12 months
Secondary	Change from baseline in Peripheral Blood Mononuclear Cell (PBMC) immune biomarkers	Some or all of these biomarkers may be assayed ex vivo: PBMC expression of mRNA encoding proteins involved in myeloid differentiation and immune regulatory function (e.g. VEGF, Arginine, INOS, IL-10, MMP9); PBMC myeloid subset production of IL-10, TGFß, IL-6, TNFa, IL-1ß, IFN?, IL-17, and GM-CSF in response to stimulation with LPS, LPS/IFN? or MIS416 ex vivo; and PBMC subset analysis of myeloid and dendritic cell subsets for immunoregulatory cell subset markers.	Up to 12 months